Table A2.
Comparison of PanOptix IOL Visual Outcomes in Published Literature.
| PanOptix Study | Eyes (n) | Int (mo) |
UDVA (logMar) | UIVA (logMar) |
UNVA (logMar) |
UDVA ≤ 20/20 (%) | UDVA ≤ 20/40 (%) | UIVA ≤ 20/20 (%) | UIVA ≤ 20/40 (%) | UNVA ≤ 20/20 (%) | UNVA ≤ 20/40 (%) | Funding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monaco [23], 2017 | 60 | 4 | 0.00 ± 0.04 | 0.23 ± 0.07 | 0.02 ± 0.06 | - | - | - | - | - | - | N |
| Garcia-Perez [24], 2017 | 58 | 1 | 0.03 ± 0.05 | 0.12 ± 0.14 | 0.02 ± 0.10 | - | - | - | - | - | - | N |
| Kohnen [25], 2017 | 54 | 3 | 0.04 ± 0.13 | 0.06 ± 0.12 | 0.06 ± 0.107 | 57 | 96 | 40 | 100 | 50 | 100 | N |
| Lawless [26], 2017 | 66 | 1, 2 | 0.01 ± 0.1 | 0.3 ± 0.14 | 0.18 ± 0.1 | 78.8 | 100 | - | - | 50 | - | N |
| De Medeiros [3], 2017 | 20 | 1–6 | 0.01 ± 0.04 * | 0.14 ± 0.05 * | −0.03 ± 0.04 * | - | - | - | - | - | - | N |
| Gundersen and Potvin [27], 2017 | 120 | 6–24 | −0.05 ± 0.07 * | - | 0.07 ± 0.07 | - | - | - | - | - | - | Y |
| Vilar [28], 2017 | 40 | 1 | 0.01 ± 0.04 | 0.14 ± 0.05 | −0.03 ± 0.04 | - | - | - | - | - | - | N |
| Böhm [29], 2018 | 27 | 3 | 0.04 ± 0.13 | 0.08 ± 0.12 | 0.06 ± 0.11 | - | - | - | - | - | - | Y |
| Escandón-García [30], 2018 | 90 | 1–2 | 0.07 ± 0.10 * | - | - | - | - | - | - | - | - | Y |
| Mencucci [31], 2018 | 120 | 3 | 0.01 ± 0.09 | 0.11 ± 0.04 | 0.17 ± 0.05 | 50 | 100 | 2 | 100 | 0 | 100 | N |
| Alió [32], 2018 | 52 | 6 | 0.07 ± 0.10 * | 0.12 ± 0.13 * | 0.16 ± 0.09 * | - | - | - | - | - | - | Y |
| Cochener [33], 2018 | 120 | 6 | 0.87 ± 0.16 d | 0.55 ± 0.12 d | 0.61 ± 0.11 d | 50 | 95 | - | - | - | - | N |
| Martínez de Carneros-Llorente [34], 2019 | 40 | 6 | 0.07 ± 0.10 | - | - | - | - | - | - | - | - | N |
| Donmez [35], 2019 | 138 | 6 | 0.02 ± 0.05 | 0.06 ± 0.07 | 0.05 ± 0.07 | - | 100 | - | 100 | - | 100 | N |
| Yesilirmak [36], 2019 | 20 | 6 | −0.14 ± 0.05 * | 0.03 ± 0.05 * | 0.00 ± 0.00 * | 100 * | 100 * | 75 * | 100 * | 100 * | 100 * | N |
| Středová [37], 2019 | 32 | 1, 27 | 0.94 ± 0.10 d | - | 1.00 ± 0.0 d | - | - | - | - | - | 96.3 | N |
| Rementería-Capelo [18], 2019 (spherical) | 166 | 3 | 0.06 ± 0.07 | 0.2 ± 0.1 | 0.05 ± 0.07 | - | - | - | - | - | - | N |
| Rementería-Capelo [18], 2019 (toric) | 84 | 3 | 0.07 ± 0.1 | 0.23 ± 0.2 | 0.07 ± 0.12 | - | - | - | - | - | - | N |
| De Medeiros [38], 2019 | 26 | 6–12 | 0.09 ± 0.00 * | 0.39 ± 0.2 * | −0.01 ± 0.16 * | - | - | - | - | - | - | Y |
| Ribeiro [39], 2020 | 60 | 3 | 0.06 ± 0.11 | 0.05 ± 0.08 | 0.05 ± 0.10 | - | - | - | - | - | - | Y |
| Nicula [40], 2020 | 128 | 12 | 0.07 ± 0.14 | 0.08 ± 0.14 | 0.07 ± 0.14 | 62.8 | - | 62.8 | - | 62 | - | N |
| Kim [41], 2020 | 88 | 3 | 0.08 ± 0.12 | 0.05 ± 0.13 | 0.09 ± 0.13 | 52 | 100 | 66 | 100 | 57 | 96 | Y |
| Kohnen [42], 2020 | 50 | 3 | 0.02 ± 0.12 | 0.12 ± 0.11 | 0.10 ± 0.11 | 68 | 100 | 29 | 100 | 32 | 100 | Y |
| Kohnen [43], 2020 | 290 | 12 | 0.02 ± 0.11 * | 0.04 ± 0.12 * | 0.07 ± 0.11 * | 70 | 99 | 51 | 98 | 44 | 97 | Y |
| Song [44], 2020 | 50 | 6 | 0.03 ± 0.08 | 0.05 ± 0.05 | 0.08 ± 0.09 | - | 100 * | - | 100 * | - | 100 * | Y |
| Lapid-Gortzak [45], 2020 | 93 | 4–6 | 0.01 ± 0.01 * | 0.05 ± 0.13 * | 0.08 ± 0.10 * | - | - | - | - | - | - | Y |
| Carreño [46], 2020 | 200 | 1 | −0.08 * | 0.03 * | −0.04 * | - | - | - | - | - | - | Y |
| Ribeiro [47], 2020 | 30 | 3 | 0.05 ± 0.09 | 0.11 ± 0.13 | 0.05 ± 0.11 | - | - | - | - | - | - | N |
| Serdiuk [48], 2020 | 28 | 6 | 0.33 ± 0.29 d | - | - | 64 | 100 | 0 | 96 | 11 | 96 | N |
| Alfonso [49], 2020 | 80 | 6 | 0.85 ± 0.19 | - | 0.71 ± 0.10 | 70 * | 100 * | 0 * | 100 * | 35 * | 100 * | N |
| Pedrotti [50], 2020 | 50 | 3 | −0.02 ± 0.09 | 0.12 ± 0.04 | 0.14 ± 0.045 | - | - | - | - | - | - | Y |
| Doroodgar [51], 2020 | 62 | 24, 48 | 0.02 ± 0.04 * | 0.04 ± 0.06 * | 0.03 ± 0.05 * | - | - | - | - | - | - | N |
| Rementería-Capelo [52], 2021 | 72 | 3 | 0.04 ± 0.06 | 0.18 ± 0.13 | 0.06 ± 0.07 | - | - | - | - | - | - | N |
| Blaylock [53], 2020 | 137 | 3 | 0.04 ± 0.09 | −0.07 ± 0.08 | 0.04 ± 0.07 | 64.7 | 100 | 94.9 | 99.3 | 73 | 100 | Y |
| Moshirfar [14], 2021 | 113 | 3 | 0.09 ± 0.13 | - | 0.16 ± 0.14 | 21 | 100 | - | - | 23 | 96 | N |
| Choi [54], 2021 | 50 | 6 | 0.04 ± 0.07 | - | 0.03 ± 0.06 | 70 | 100 | - | - | - | - | Y |
| Ramamurthy [55], 2021 | 141 | 3 | 0.09 ± 0.14 | 0.12 ± 0.15 | 0.14 ± 0.15 | 53.7 * | 100 * | 34.8 * | 98.5 * | 31.8 * | 92.4 * | Y |
| Ison [56], 2021 | 134 | 1 | 0.01 ± 0.10 * | - | 0.14 ± 0.06 * | 72 * | 100 * | - | - | - | - | N |
| Yoo [57], 2021 | 25 | 3 | 0.08 ± 0.14 | - | 0.05 ± 0.08 | - | - | - | - | - | - | Y |
| Galvis [58], 2022 | 130 | 1.5+ | 0.04 ± 0.06 * | 0.07 ± 0.08 * | 0.05 ± 0.08 * | 63.1 | 100 | - | - | - | 100 | N |
| Sandoval [59], 2022 | 56 | 3 | 0.04 ± 0.09 | 0.13 ± 0.10 | 0.13 ± 0.07 | - | - | - | - | - | - | Y |
| Blaylock [60], 2022 | 35 | 3 | 0.09 ± 0.08 | 0.01 ± 0.12 | 0.05 ± 0.10 | 28.6 | 100 | 77.8 | 100 | 65.6 | 100 | Y |
| Imburgia [61], 2022 | 32 | 12 | 0.01 ± 0.06 | 0.09 ± 0.05 | 0.04 ± 0.05 | 75 | - | 19 | 100 | 56 | 100 | N |
| FDA Trial [20], 2019 | 129 | 6 | - | - | - | 44.9 | 97.6 | 37 | 96.9 | 25.2 | 95.3 | Y |
| Current Study, 2022 | 119 | 6 | 0.09 ± 0.16 | 0.02 ± 0.12 | 0.02 ± 0.07 | 36 | 98 | 4 | 87 | 15 | 85 | N |
Abbreviations: Int = postoperative follow-up interval; UDVA = uncorrected distance visual acuity; UIVA = uncorrected intermediate visual acuity; UNVA = uncorrected near visual acuity; d = decimal; * = binocular visual acuity (all values are monocular unless otherwise noted). Parameters such as distance-corrected visual acuity were not included, given that the current study did not use these parameters. In all instances, if two distances existed for one parameter, the one closest to the distance used in the current study was recorded in this table. For example, if there were two distances measured for UIVA (80 cm and 60 cm) the 60 cm measurement was used, given that it is closer to the current study’s measurement of UIVA at 66 cm.